Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.